Canton Strategic Holdings, Inc. (CNTN): Nasdaq/NYSE listing notice — Hillstream BioPharma receives Nasdaq notice for bid price below $1.00 per share

Canton Strategic Holdings, Inc.

Nasdaq notified Hillstream on June 12, 2023 that bid price closed below $1.00 for 30 consecutive business days.
Company has 180 days until Dec 11, 2023 to regain compliance by closing at $1.00 for 10 consecutive days.
If not compliant by Dec 11, may qualify for second 180-day period; otherwise delisting with appeal option.
Hillstream intends to actively monitor closing bid price and consider available options to regain compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Canton Strategic Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

June 12, 2023, Hillstream BioPharma, Inc. (the “Company”) received written notice (the “Notice”) from the Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the bid price for the Company’s common stock (the “Common Stock”), for the last 30 consecutive business days, had closed below the minimum $1.00 per share and, as a result, the Company is not in compliance with the $1.00 minimum bid price requirement for the continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). The Notice has no effect at this time of the Common Stock, which continues to trade on

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Canton Strategic Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-021669

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.